BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27306811)

  • 1. [A Retrospective Analysis of Epiphora Due to Docetaxel].
    Noguchi Y; Kawashima Y; Kawara H; Tokuyama Y; Tamura Y; Uchiyama K; Shimizu Y
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):737-41. PubMed ID: 27306811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epiphora in lung cancer patients receiving docetaxel: a case series.
    Yamagishi T; Ochi N; Yamane H; Hasebe S; Takigawa N
    BMC Res Notes; 2014 May; 7():322. PubMed ID: 24886618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of excessive tearing as a side effect of docetaxel.
    Esmaeli B
    Clin Breast Cancer; 2005 Feb; 5(6):455-7. PubMed ID: 15748466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
    Esmaeli B; Amin S; Valero V; Adinin R; Arbuckle R; Banay R; Do KA; Rivera E
    J Clin Oncol; 2006 Aug; 24(22):3619-22. PubMed ID: 16877729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.
    Tu AH; Chang EL
    Ophthalmology; 2005 Aug; 112(8):1469-71. PubMed ID: 15953639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
    Esmaeli B; Hortobagyi G; Esteva F; Valero V; Ahmadi MA; Booser D; Ibrahim N; Delpassand E; Arbuckle R
    Ann Oncol; 2002 Feb; 13(2):218-21. PubMed ID: 11885997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity.
    Tsalic M; Gilboa M; Visel B; Miller B; Haim N
    Med Oncol; 2006; 23(1):57-61. PubMed ID: 16645230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
    Esmaeli B; Hortobagyi GN; Esteva FJ; Booser D; Ahmadi MA; Rivera E; Arbuckle R; Delpassand E; Guerra L; Valero V
    Ophthalmology; 2002 Jun; 109(6):1188-91. PubMed ID: 12045065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.
    Esmaeli B; Valero V; Ahmadi MA; Booser D
    Ophthalmology; 2001 May; 108(5):994-5. PubMed ID: 11320034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-associated epiphora.
    Kintzel PE; Michaud LB; Lange MK
    Pharmacotherapy; 2006 Jun; 26(6):853-67. PubMed ID: 16716138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
    Esmaeli B; Hidaji L; Adinin RB; Faustina M; Coats C; Arbuckle R; Rivera E; Valero V; Tu SM; Ahmadi MA
    Cancer; 2003 Aug; 98(3):504-7. PubMed ID: 12879466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
    Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
    JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
    Leyssens B; Wildiers H; Lobelle JP; Gillis A; Paridaens R; Mombaerts I
    Ann Oncol; 2010 Feb; 21(2):419-423. PubMed ID: 19622592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction.
    Mansur C; Pfeiffer ML; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2017; 33(1):9-12. PubMed ID: 27429222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.
    Chan A; Su C; de Boer RH; Gajdatsy A
    J Clin Oncol; 2013 Jun; 31(17):2123-7. PubMed ID: 23650421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
    Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important?
    Esmaeli B; Valero V
    J Clin Oncol; 2013 Jun; 31(17):2076-7. PubMed ID: 23650413
    [No Abstract]   [Full Text] [Related]  

  • 18. Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction.
    Girard B; Piaton JM; Keller P; Abadie C; Nguyen TH
    J Fr Ophtalmol; 2017 Oct; 40(8):661-665. PubMed ID: 28847443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect.
    Kalra R; Chavada B; Madhani NR; Purohit B; Tripathi CB
    Curr Drug Saf; 2018; 13(1):62-64. PubMed ID: 28933276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
    Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
    Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.